Arcadia Biosciences (RKDA) Director Kevin Comcowich Receives Award

What Happened

• Kevin Comcowich, a director of Arcadia Biosciences, was granted a derivative award covering 23,000 shares on September 10, 2026. The Form 4 reports the acquisition as an award/derivative with a reported price of $0.00 — this is a grant of an equity award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-09-10; Form filed: 2026-09-14 (timely filing).
• Transaction type: Grant/Award (derivative), 23,000 shares; reported price $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: The option award will become 100% vested and exercisable on the earlier of (i) September 10, 2027 or (ii) the date of the issuer’s next Annual Meeting of Stockholders, subject to continued service.
• No exercise or sale occurred at grant; this is a future right to acquire shares (subject to vesting).

Context

• This filing documents an option-like award, which gives the director the right to acquire shares in the future if vesting conditions are met. It does not represent immediate stock ownership or a cash transaction, nor does it signal an immediate buy/sell decision. Such grants are a common form of director compensation.